The purpose of Strepsils Intensive is to deliver focused symptomatic relief by directly addressing the primary manifestations of throat inflammation. It is commonly used when symptoms create noticeable functional strain, offering supportive assistance.

The lozenge is indicated for the symptomatic relief of sore throat in adults and adolescents over 12 years. The medicine is commonly used across conditions presenting with acute episodes, such as pharyngitis and symptoms linked to upper respiratory discomfort.

Easing Pain and Inflammation in Acute Sore Throat

Strepsils Intensive is applied in contexts where discomfort arises from acute pharyngitis and related inflammatory or irritative states. This helps address the essential symptomatic domains of local pain and swelling, which may appear suddenly. The therapeutic benefit contributes to easing the overall symptom load, which may help patients cope more steadily with difficult episodes.

Supporting Functional Comfort

This formulation helps address symptoms that create noticeable functional strain, specifically the difficulty and pain associated with swallowing. When inflammation interferes with this function, the medicine offers symptomatic relief that contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic periods. The medication is commonly used when symptoms become more disruptive during flare-ups or when symptomatic relief is needed.

---

Quick Fact: Relief for Functional Strain The lozenge is commonly used to help with symptoms related to physical discomfort, and assists with maintaining functional stability during symptomatic periods.

Regulatory References

1. Summary of Product Characteristics (SmPC) from the Irish Health Products Regulatory Authority (HPRA)

Strepsils Intensive (Flurbiprofen) is approved for use by adults and adolescents over the age of 12 years. The medicine is formally contraindicated for children under this minimum age threshold, as stated in regulatory documentation.

Contraindicated Populations

Use is strictly prohibited for individuals with specific health statuses, as mandated by official regulatory bodies. These absolute contraindications include a known hypersensitivity to Flurbiprofen, Acetylsalicylic acid (Aspirin), or any other NSAID. The medicine must not be used by patients with severe heart failure, severe renal failure, or severe hepatic failure. Furthermore, individuals with active or a history of recurrent peptic ulcer/haemorrhage are ineligible.

Use Restrictions

Specific limitations apply to women in a reproductive state. The medicine is contraindicated during the last trimester of pregnancy. Use during the first and second trimesters and while lactating is not recommended and should be avoided unless clearly necessary. Caution is also advised for the elderly population, due to an increased frequency of NSAID-related adverse reactions.

Interactions with Other Medicines and Products

The interaction profile for flurbiprofen lozenges is based on restrictions documented in official regulatory sources concerning its Nonsteroidal Anti-inflammatory Drug (NSAID) activity.

Formally Documented Interaction Risks

Interacting Substance/Class	Official Interaction Description
Other NSAIDs (including selective COX-2 inhibitors)	Contraindicated due to an officially documented Additive Pharmacodynamic Risk, increasing the likelihood of serious gastrointestinal adverse events.
Acetylsalicylic Acid (Aspirin)	Concomitant use is restricted/avoided due to increased risk of GI toxicity and the potential for reduced flurbiprofen serum levels.
Anticoagulants (e.g., Warfarin)	Documented to enhance the effects of these agents, significantly increasing the risk of hemorrhage and bleeding.

Exposure and Timing Constraints

Co-administration with flurbiprofen may lead to Pharmacokinetic Exposure Modification for certain medicines. Official documentation states flurbiprofen may increase the plasma concentration of Lithium and Methotrexate by reducing their clearance. For Methotrexate, an administration window restriction is noted, with co-administration within 24 hours before or after posing a risk of elevated levels. NSAIDs should also not be used for 8–12 days following Mifepristone administration.

Population-Specific Notes

Regulatory documents highlight that interactions resulting in Renal Function Deterioration Risk with ACE Inhibitors or ARBs are especially relevant for elderly patients and individuals who are volume-depleted.

The compound flurbiprofen acts through two primary mechanistic domains to modulate tissue response.

---

Inhibition of Prostaglandin Biosynthesis

This domain acts within the key pathway of the cyclooxygenase (COX) enzyme system. Flurbiprofen is a non-selective inhibitor of both COX-1 and COX-2 enzymes, thereby directly engaging the initial molecular steps that regulate eicosanoid production. By blocking these enzymes, the compound suppresses the synthesis of prostaglandins, which are lipid mediators that influence local tissue response.

---

Modulation of Local Mediator Signaling

This mechanism modulates pathways within the local mucosal tissue. The resulting reduction in pro-inflammatory prostaglandins contributes to a decrease in localized pro-inflammatory signaling. This pathway adjustment modifies the activity profile of local mediators, resulting in an altered state within the targeted tissue.

The lozenge containing Flurbiprofen 8.75 mg is administered via the oromucosal route, which involves slowly dissolving the unit dose in the mouth to ensure delivery to the throat lining. The product is intended for short-term use only, with the total course of treatment restricted to a maximum of three days.

The standard single dose for adults and adolescents over the age of 12 years is one lozenge. This dose is part of an as-needed regimen and may be repeated, with a minimum interval of 3 hours between administrations. A strict limit of 5 lozenges must not be exceeded within any 24-hour period. The lowest effective dose should be used for the shortest duration necessary to manage symptoms.

Administration requires the lozenge to be dissolved slowly, and a key procedural condition is to continuously move the lozenge around the mouth whilst sucking. This technique promotes local distribution. For patients with mild to moderate impairment of hepatic or renal function, no specific dose reduction is required. The medicine is not indicated for use in children under 12 years of age.

Research evidence / Overview of Studies for Strepsils Intensive (Flurbiprofen Lozenge)

---

Evidence from Clinical Trials for Acute Sore Throat Relief

The main body of evidence exploring the patterns of symptom change for this medicine comes from randomized controlled trials (RCTs). These studies compare the active lozenge against a placebo (an inactive lozenge). The goal of these trials was to measure patient-reported symptom patterns. The research examined the measurement of symptoms related to acute episodes, such as those associated with an upper respiratory tract infection (URTI).

How Studies Measured Symptom Change

The studies used specific scales to track patient-reported outcomes describing perceived discomfort. The primary outcomes examined included measuring the intensity of pain in the throat and monitoring the patterns of reported pain. Another key measure was an assessment of functional discomfort, specifically the degree of difficulty swallowing (dysphagia). These outcomes related to daily functioning were a focus in trials assessing short-term or episodic symptom patterns.

Study Focus on Specific Populations

The clinical research primarily included two main groups: adults and adolescents over 12 years of age. Patients enrolled in these trials often included those experiencing periods of heightened symptoms, such as moderate-to-severe sore throat discomfort, at baseline. Research has also studied specific subgroups, such as patients with a confirmed Streptococcus throat infection who were also taking concomitant antibiotics.

Research Gaps and What Remains Uncertain

One primary area of uncertainty involves the long-term effects. Because the trials focused on acute episodes, there is limited information for long-term outcomes beyond the study duration. Furthermore, studies note that the primary outcomes related to physical discomfort are subjective. Researchers have noted the inherent difficulty in distinguishing the measured symptom patterns from the temporary, non-medicinal, soothing effects of the lozenge formulation itself. Comparative evidence for certain populations remains insufficient.

Key Studies & References Public Assessment Report Scientific discussion Flurbiprofen HTP 8.75 mg lozenges sugar-free (orange)

Common questions about Strepsils intensive (FAQ)

---

Q: Are there any known issues with taking Strepsils intensive with common pain relievers like paracetamol?

Official regulatory documents and professional interaction profiles for the flurbiprofen lozenge typically list other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and aspirin as restricted combinations. They do not generally list paracetamol (acetaminophen) as a formal interaction risk, but combination use is not typically addressed in the product-specific label.

---

Q: Can Strepsils intensive be used by someone with high blood pressure?

Regulatory warnings describe the need for caution for patients with a history of hypertension (high blood pressure) or heart failure. This is because Nonsteroidal Anti-inflammatory Drugs (NSAIDs) have been associated with reports of fluid retention and oedema (swelling) in some individuals.

---

Q: Can someone who is allergic to aspirin use Strepsils intensive?

The medicine is contraindicated (use is prohibited) for patients who have previously experienced hypersensitivity reactions, such as asthma or hives, in response to acetylsalicylic acid (aspirin) or any other Nonsteroidal Anti-inflammatory Drug (NSAID). This restriction is explicitly stated in regulatory documents.

---

Q: Can Strepsils intensive be used if I am taking blood thinning medication?

Official documentation notes that flurbiprofen may enhance the effects of anticoagulants (e.g., warfarin), which are blood thinners, significantly increasing the risk of hemorrhage and bleeding. The combination of flurbiprofen and anticoagulants is subject to caution in regulatory documents.

---

Q: What other medicines are officially noted as having an interaction with Strepsils intensive?

Regulatory documents describe formal interaction risks with several classes of medicines due to the NSAID activity of flurbiprofen. These include other NSAIDs and aspirin, anticoagulants, lithium, methotrexate, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs).

---

Q: Is Strepsils intensive effective against pain caused by bacterial infections?

The product’s general purpose is to provide symptomatic relief for inflammation and pain. Clinical research has included patients with confirmed bacterial (Streptococcus) throat infection who were also receiving concomitant antibiotics. The lozenge itself is an anti-inflammatory, not an antibiotic.

---

Q: How quickly do people usually feel the effects of Strepsils intensive?

Clinical studies have examined patient-reported outcomes for the lozenge. The research indicated that the first perceived pain relief was reported by patients as early as approximately 11 to 12 minutes after administration.

---

Q: Is it common to feel a strange taste after using Strepsils intensive?

Official reports on side effects note an unusual taste (dysgeusia) as a possible, generally mild, and temporary adverse effect of the medicine.

---

Q: How long does the relief from one Strepsils intensive lozenge typically last?

Clinical evidence for the lozenge formulation has shown that the pain-reducing effects were demonstrated for approximately 3.5 to 4 hours. This time frame is reflected in the guidance regarding the minimum interval between doses.

---

Q: Is Strepsils intensive safe for people with a history of asthma?

Regulatory warnings indicate that the lozenges are subject to caution for patients with a history of bronchial asthma or allergic disease. This is because Nonsteroidal Anti-inflammatory Drugs (NSAIDs) have been reported to potentially trigger bronchospasm in these sensitive individuals.

---

Q: Are there any reported side effects that affect sleep?

Official regulatory reports on undesirable effects list both insomnia (difficulty sleeping) and somnolence (unusual drowsiness or sleepiness) as potential, though generally uncommon, side effects of the medication.

---

Q: Can the effectiveness of Strepsils intensive be affected by smoking?

Some professional guidance documents note that the combined use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) with smoking tobacco may increase the risk of gastrointestinal side effects, such as peptic ulcer or bleeding.

---

Q: What evidence supports the use of Strepsils intensive over a simple throat sweet?

Clinical trials for the lozenge were conducted against a placebo (an inactive lozenge that does not contain the active drug). The results demonstrated that the active drug's effect provided pain reduction that was significantly differentiated from the temporary, soothing effect of the lozenge base alone.

---

Q: Can Strepsils intensive be used by people who are lactose intolerant?

The specific inactive ingredients (excipients) should be reviewed on the product’s official label. For example, some sugar-free versions are documented to contain Isomalt and Maltitol, and may carry warnings for rare hereditary problems of fructose intolerance. Inactive ingredients can vary by product version.

---

Q: What is the maximum duration of use mentioned in official documents for Strepsils intensive?

Official regulatory guidelines recommend that this product is intended for short-term use only. The maximum course of treatment is restricted to three days in official regulatory guidelines.

---

Q: Does Strepsils intensive have a listed interaction with alcohol?

Yes, official documents state that consuming alcohol while using the product may increase the risk of adverse reactions. This risk is primarily associated with bleeding in the gastrointestinal tract.

---

Q: What is the typical time frame for noticing an improvement in symptoms when using Strepsils intensive?

Clinical studies have reported the onset of action for a meaningful reduction in throat pain to be within under 45 minutes of administering the lozenge.

---

Q: Are there any known cases of Strepsils intensive affecting liver function?

The medicine is contraindicated (use is prohibited) in patients with severe hepatic failure (severe liver failure). Official warnings also mention that abnormal liver function tests have been reported as a common side effect of the medicine.

---

Q: Is the feeling of numbness in the mouth expected when using Strepsils intensive?

The official side effect report lists pharyngeal paresthesia (an abnormal sensation in the throat) as a common effect. This effect may be experienced by some users as a feeling of tingling or mild numbness in the throat area.

---

Q: Can Strepsils intensive be used for pain in parts of the mouth other than the throat?

The medicine is specifically indicated for the short-term symptomatic relief of pain and inflammation associated with a sore throat, focusing on the oropharyngeal area. This covers the back of the mouth and the throat tissues.

---

Q: Does Strepsils intensive contain any sugar substitutes like aspartame?

The specific inactive ingredients (excipients) should be reviewed on the product's official label. For example, some sugar-free formulations are documented to contain aspartame (a source of phenylalanine) as an excipient.

---

Q: What research has been conducted on the safety profile of Strepsils intensive in older adults?

Official warnings emphasize that the elderly population has an increased frequency of adverse reactions to Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Regulatory documents state that a general dose recommendation cannot be given due to limited clinical experience in this specific age group.

---

Q: Are there specific official guidelines about driving or operating machinery after using Strepsils intensive?

Official documents advise that patients who experience side effects such as dizziness or visual disturbance are advised in official documents to refrain from driving or operating machinery. These effects are listed as possible, though generally uncommon, side effects.

---

Q: Is it common for Strepsils intensive to cause irritation to the throat lining?

Yes, official side effect documents list oral irritation and mouth pain as common adverse reactions, meaning they may affect up to 1 in 10 people.

How to Store and Dispose of Strepsils Intensive

Storage of Strepsils Intensive lozenges must adhere to official regulatory conditions to maintain the stability of Flurbiprofen.

Storage Requirements

• Temperature: Store at or below 25 C; the product must not be refrigerated or frozen.
• Protection: Keep the lozenges in the original package, protected from light and moisture, in a dry place.
• Child Safety: The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product must be disposed of in accordance with local requirements. It is officially required not to throw away any medicines via wastewater or household waste to protect the environment.